▲ +80.84% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nephros in the last 3 months. The average price target is $14.25, with a high forecast of $16.00 and a low forecast of $12.50. The average price target represents a 80.84% upside from the last price of $7.88.
The current consensus among 2 polled investment analysts is to buy stock in Nephros. This rating has held steady since September 2019, when it changed from a Hold consensus rating.
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.